D-dimer and C-reactive Protein Blood Levels Over Time Used to Predict Pulmonary Embolism in Two COVID-19 Patients

Authors

• Yael Becher Geriatrics and Internal Medicine B Department, Sheba Medical Center, Ramat-Gan, Israel; Aff. to Sackler School of Medicine, Tel-Aviv University, Israel
• Leonid Goldman Geriatrics and Internal Medicine B Department, Sheba Medical Center, Ramat-Gan, Israel; Aff. to Sackler School of Medicine, Tel-Aviv University, Israel
• Nadav Schacham Geriatrics and Internal Medicine B Department, Sheba Medical Center, Ramat-Gan, Israel; Aff. to Sackler School of Medicine, Tel-Aviv University, Israel
• Irina Gringauz Geriatrics and Internal Medicine B Department, Sheba Medical Center, Ramat-Gan, Israel; Aff. to Sackler School of Medicine, Tel-Aviv University, Israel
• Dan Justo Geriatrics and Internal Medicine B Department, Sheba Medical Center, Ramat-Gan, Israel; Aff. to Sackler School of Medicine, Tel-Aviv University, Israel

dan.Justo@sheba.health.gov.il

Keywords

Abstract

The diagnosis of pulmonary embolism is challenging in symptomatic COVID-19 patients since shortness of breath, chest pain, tachycardia, tachypnoea, fever, oxygen desaturation and high D-dimer blood levels might be features of both diseases. We present two COVID-19 patients in whom pulmonary embolism was suspected (and diagnosed) due to a discrepancy between an increase in D-dimer blood levels and a decrease in C-reactive protein blood levels over time. We believe that an opposite change in the blood levels of both biomarkers over time may be used as a novel method to predict pulmonary embolism in COVID-19 patients.